Caris Life Sciences, Inc. Common Stock (CAI)vsRoyalty Pharma Plc (RPRX)
CAI
Caris Life Sciences, Inc. Common Stock
$16.49
-4.57%
HEALTHCARE · Cap: $5.08B
RPRX
Royalty Pharma Plc
$55.02
-0.76%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 169% more annual revenue ($2.44B vs $907.29M). RPRX leads profitability with a 33.9% profit margin vs 3.8%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
CAI
Hold44
out of 100
Grade: D
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CAI.
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 78.8% year-over-year
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
ROE of 5.7% — below average capital efficiency
3.8% margin — thin
Operating margin of 2.4%
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CAI
The strongest argument for CAI centers on Revenue Growth, Debt/Equity. Revenue growth of 78.8% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : CAI
The primary concerns for CAI are EPS Growth, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
CAI profiles as a hypergrowth stock while RPRX is a mature play — different risk/reward profiles.
CAI is growing revenue faster at 78.8% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RPRX scores higher overall (65/100 vs 44/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caris Life Sciences, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CAI International, Inc. is a transportation finance company in the United States, Switzerland, France, Korea, Singapore, Rest of Asia, Rest of Europe, and internationally. The company is headquartered in San Francisco, California.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?